Expertise in
1
conditions

Salvador M. Algarra

Pamplona, NC, ES 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
1
conditions
Pamplona, NC, ES 

Overview

Salvador Algarra practices practicing medicine in Pamplona, Spain.

Mr. Algarra is highly rated in 1 condition, according to our data. His clinical expertise encompasses Melanoma, Metastatic Uveal Melanoma, Uveal Melanoma, Neuroendocrine Tumor, and Vertebroplasty.

He is actively involved in clinical research, co-authoring 12 peer reviewed articles and participating in 5 clinical trials.

Gender

Male

Locations

Pamplona, NC, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain
Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain
Enrollment Status: Recruiting
Publish Date: April 04, 2025
Intervention Type: Other
Phase II, Multicentre Clinical Trial to Evaluate the Activity of Encorafenib and Binimetinib Administered Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain
Phase II, Multicentre Clinical Trial to Evaluate the Activity of Encorafenib and Binimetinib Administered Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain
Enrollment Status: Completed
Publish Date: May 21, 2025
Intervention Type: Drug, Radiation
Study Drugs: Encorafenib, Binimetinib
Study Phase: Phase 2
A Three Arms Prospective, Randomized Phase II Study to Evaluate the Best Sequential Approach With Combo Immunotherapy (Ipilimumab/Nivolumab) and Combo Target Therapy (LGX818/MEK162) in Patients With Metastatic Melanoma and BRAF Mutation
A Three Arms Prospective, Randomized Phase II Study to Evaluate the Best Sequential Approach With Combo Immunotherapy (Ipilimumab/Nivolumab) and Combo Target Therapy (LGX818/MEK162) in Patients With Metastatic Melanoma and BRAF Mutation
Enrollment Status: Completed
Publish Date: June 07, 2024
Intervention Type: Drug
Study Drugs: LGX818, MEK162, Nivolumab, Ipilimumab
Study Phase: Phase 2
A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma
A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Combination product
Study Drug: Melphalan/Hepatic Device System
Study Phase: Phase 3
A Multicenter, Single Arm, Phase 2 Clinical Study on the Combination of Radiation Therapy and Ipilimumab, for the Treatment of Patients With Melanoma and Brain Metastases
A Multicenter, Single Arm, Phase 2 Clinical Study on the Combination of Radiation Therapy and Ipilimumab, for the Treatment of Patients With Melanoma and Brain Metastases
Enrollment Status: Completed
Publish Date: November 08, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

12 Total Publications

Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801.
Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801.
Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: March 12, 2025

Frequently Asked Questions about Salvador M. Algarra

Is Salvador M. Algarra a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Salvador M. Algarra is classified as an Advanced expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Salvador M. Algarra participate in research or clinical trials?

Yes. Salvador M. Algarra has published 12 articles and abstracts on conditions like Melanoma. You can view a list of Salvador M. Algarra's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Algarra's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile